Publication date: Available online 15 July 2017
Source:European Journal of Surgical Oncology (EJSO)
Author(s): Kozo Kataoka, Kenichi Nakamura, Junki Mizusawa, Ken Kato, Junko Eba, Hiroshi Katayama, Taro Shibata, Haruhiko Fukuda
BackgroundThere have been no reports evaluating progression-free survival (PFS) as a surrogate endpoint in resectable esophageal cancer. This study was conducted to evaluate the trial level correlations between PFS and overall survival (OS) in resectable esophageal cancer with preoperative therapy and to explore the potential benefit of PFS as a surrogate endpoint for OS.MethodsA systematic literature search of randomized trials with preoperative chemotherapy or preoperative chemoradiotherapy for esophageal cancer reported from January 1990 to September 2014 was conducted using PubMed and the Cochrane Library. Weighted linear regression using sample size of each trial as a weight was used to estimate coefficient of determination (R2) within PFS and OS. The primary analysis included trials in which the HR for both PFS and OS was reported. The sensitivity analysis included trials in which either HR or median survival time of PFS and OS was reported. In the sensitivity analysis, HR was estimated from the median survival time of PFS and OS, assuming exponential distribution.ResultsOf 614 articles, 10 trials were selected for the primary analysis and 15 for the sensitivity analysis. The primary analysis did not show a correlation between treatment effects on PFS and OS (R2 0.283, 95%CI [0.00-0.90]). The sensitivity analysis did not show an association between PFS and OS (R2 0.084, 95%CI [0.00-0.70]).ConclusionAlthough the number of randomized controlled trials evaluating preoperative therapy for esophageal cancer is limited at the moment, PFS is not suitable for primary endpoint as a surrogate endpoint for OS.